Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
21596 | 355 | 31.0 | 85% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | M 3M3FBS | Author keyword | 17 | 100% | 2% | 8 |
2 | OC2 | Author keyword | 11 | 78% | 2% | 7 |
3 | NPC 14686 | Author keyword | 8 | 100% | 1% | 5 |
4 | FENDILINE | Author keyword | 7 | 44% | 3% | 12 |
5 | NURSERY | Address | 7 | 24% | 7% | 24 |
6 | BFTC CELLS | Author keyword | 6 | 71% | 1% | 5 |
7 | CHRON DIS HLTH PROMOT | Address | 6 | 16% | 9% | 33 |
8 | BLADDER CELL CARCINOMA | Author keyword | 4 | 67% | 1% | 4 |
9 | OC2 CELLS | Author keyword | 4 | 75% | 1% | 3 |
10 | MG63 CELLS | Author keyword | 4 | 24% | 4% | 14 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | M 3M3FBS | 17 | 100% | 2% | 8 | Search M+3M3FBS | Search M+3M3FBS |
2 | OC2 | 11 | 78% | 2% | 7 | Search OC2 | Search OC2 |
3 | NPC 14686 | 8 | 100% | 1% | 5 | Search NPC+14686 | Search NPC+14686 |
4 | FENDILINE | 7 | 44% | 3% | 12 | Search FENDILINE | Search FENDILINE |
5 | BFTC CELLS | 6 | 71% | 1% | 5 | Search BFTC+CELLS | Search BFTC+CELLS |
6 | BLADDER CELL CARCINOMA | 4 | 67% | 1% | 4 | Search BLADDER+CELL+CARCINOMA | Search BLADDER+CELL+CARCINOMA |
7 | OC2 CELLS | 4 | 75% | 1% | 3 | Search OC2+CELLS | Search OC2+CELLS |
8 | MG63 CELLS | 4 | 24% | 4% | 14 | Search MG63+CELLS | Search MG63+CELLS |
9 | CA2 STORES | 4 | 16% | 6% | 20 | Search CA2+STORES | Search CA2+STORES |
10 | SIRC | 3 | 43% | 2% | 6 | Search SIRC | Search SIRC |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PHOSPHOLIPASE C ACTIVATOR | 8 | 100% | 1% | 5 |
2 | CA2 MOVEMENT | 3 | 50% | 1% | 4 |
3 | OVULATION INDUCING AGENT | 2 | 67% | 1% | 2 |
4 | ANTIDEPRESSANT SERTRALINE | 2 | 29% | 1% | 5 |
5 | CASPASE 3 PATHWAYS | 1 | 50% | 1% | 2 |
6 | INTRACELLULAR CA2 LEVELS | 1 | 100% | 1% | 2 |
7 | W 7 | 1 | 50% | 1% | 2 |
8 | ENHANCED CELL DEATH | 1 | 40% | 1% | 2 |
9 | ECONAZOLE | 1 | 17% | 1% | 5 |
10 | ANTAGONIST SUBGROUPS | 1 | 50% | 0% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
New red-fluorescent calcium indicators for optogenetics, photoactivation and multi-color imaging | 2014 | 3 | 148 | 9% |
Imidazole-induced elevations of intracellular calcium in HL-60 cells: Effect of inhibition of phospholipase C by the steroidal maleimide U73122 | 2006 | 0 | 113 | 20% |
Secretion and Hydrolysis of ATP by Ehrlich Ascites Tumor Cells during the Centrifugation. Dependence on Calcium and Temperature | 2010 | 0 | 15 | 13% |
Polycarboxylate fluorescent indicators as ion concentration probes in biological systems | 2002 | 7 | 101 | 10% |
Pharmacological actions of calmidazolium, a calmodulin antagonist, in cardiovascular system | 2000 | 3 | 32 | 9% |
FENDILINE - A REVIEW OF ITS BASIC PHARMACOLOGICAL AND CLINICAL PROPERTIES | 1987 | 30 | 31 | 6% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NURSERY | 7 | 24% | 6.8% | 24 |
2 | CHRON DIS HLTH PROMOT | 6 | 16% | 9.3% | 33 |
3 | SECT ALLERGY IMMUNOL RHEUMATOL | 3 | 16% | 4.5% | 16 |
4 | ARTHRITIS IMMUNE DISORDER | 1 | 40% | 0.6% | 2 |
5 | ARTHRIT IMMUNE DISORDER | 1 | 16% | 1.1% | 4 |
6 | ARSNEUROSCI | 1 | 50% | 0.3% | 1 |
7 | DEP MED EDUC | 1 | 50% | 0.3% | 1 |
8 | AIDRC | 0 | 33% | 0.3% | 1 |
9 | EXCELLENCE PHYSIOPATHOL CELL DIFFERENTIAT | 0 | 33% | 0.3% | 1 |
10 | ALAFI NEUROIMAGING | 0 | 25% | 0.3% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000158696 | STIM1//ORAI1//ORAI |
2 | 0.0000107642 | NORBORMIDE//LOE 908//RAT TOXICANT |
3 | 0.0000107262 | TAT BH4//MOL CELLULAR SIGNALING//BIOEMERGENCES IBISA |
4 | 0.0000097515 | DPTO CITOL HISTOL NORMAL PATOL//4 METHYLTHIOAMPHETAMINE 4 MTA//ALDOMET |
5 | 0.0000089256 | PHARMACEUT CARE CLIN PHARM//BRAIN NEURON//BISABOLOLOXIDE A |
6 | 0.0000085381 | INOSITOL 1 4 5 TRISPHOSPHATE RECEPTOR//IP3 RECEPTOR//CALCIUM OSCILLATIONS |
7 | 0.0000085047 | META NISOLDIPINE//VOLTAGE ACTIVATED//M NISOLDIPINE |
8 | 0.0000084990 | THAPSIA GARGANICA//THAPSIA VILLOSA//LASERPITIUM ZERNYI |
9 | 0.0000074141 | NUCLEAR ION CHANNELS//NUCLEOPLASMIC RETICULUM//NUCLEAR CA2 |
10 | 0.0000073829 | CELLULAR CALCIUM HOMEOSTASIS//FERRIC LACTATE//PATHOL ANAT CYTOL SERV |